Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

surveys show — and now a major new study has revealed a long list of benefits and some little-known risks. Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...

We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...

A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...

Novo NOrdisk (NVO) stock drops as Medicare selects 15 additional Part D drugs including its weight loss drug Wegovy for ...